EPS Creative Health Technology Group Limited announces that Mr. Okoso Satoshi has tendered his resignation as an executive Director, the chairman of the Board; and the chief executive officer of the Company, all with effect from 1 November 2023 in order to focus on his personal and other business engagements. Mr. Gao Feng has tendered his resignation as an executive Director; an authorised representative of the Company under the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited; an authorised representative under Part 16 of the Companies Ordinance; an the chief strategy officer of the Company, all with effect from 1 November 2023 in order to devote more time to his personal and other business commitments. Mr. Xia Xiangming has tendered his resignation as a non-executive Director and a member of the audit committee of the Board with effect from 1 November 2023 in order to focus on his personal and other business engagements.

The Board announced that with effect from 1 November 2023, Mr. Shimada Tatsuji has been appointed as an Managing Corporate Officer of EPS Holdings Inc., which is a controlling shareholder of the Company. Mr. Shimada joined EPS Japan in October 2018 and has over 39 years of experience in pharmaceutical business. Prior to joining EPS Japan, Mr. Shimada worked in Chugai Pharmaceutical Co.

Ltd., from 1984 to 2018 in which he had been the chief executive officer of Chugai Pharma Taiwan Ltd. and the International Marketing Manager of Chugai-Rhone-Poulenc SA, Paris France. Mr. Shimada is a colleague of Mr. Miyano Tsumoru, Mr. Haribayashi Keikyo, Mr. Maezaki Masahiro, the existing executive Directors, and Mr. Kusaba, a newly appointed non-executive Director, in EPS Japan. Mr. Shimada graduated from Waseda University in Tokyo, Japan, majoring in B.A. Education.

He also received an MBA degree from Washington University, MO USA in 1999. Mr. Miyazato, aged 58, started his early career in Credit Suisse, and JP Morgan as an investment banker, and then joined Nikko Asset Management as a fund manager where he created the cross-border arbitrage hedge fund and China-focus pilot fund. Mr. Miyazato founded Sunrise Oriental Japan LLC which aims at connecting China and Japan, as well as the rest of Asia regarding to the cross-border corporate interactions and had even served as the vice chairman of the OTC Business Committee of the Securities Association of China and the vice chairman of the Shanghai Cross-border Business Committee.

Mr. Miyazato graduated from Fudan University in Shanghai majoring in genetics. He also received his second degree from Tokyo University in Tokyo majoring in biophysics and biochemistry. Mr. Chiu, aged 59, has been appointed as the company secretary of the Company, a LR Authorised Representative and a CO Authorised Representative since 30 June 2021.

He has over 37 years of experience in overseeing accounting, auditing, corporate finance, merger and acquisition, taxation and company secretarial business. He is a Hong Kong practicing Certified Public Accountants and a fellow member of Hong Kong Institute of Certified Public Accountants. Prior to joining the Group, Mr. Chiu has been the founder of C.T. Chiu & Co., CPA and has also worked in a multinational company.

Mr. Chiu graduated from the Hong Kong Polytechnic University majoring in accounting. Mr. Chiu is also a director of a subsidiary of the Company. Mr. Kusaba, aged 47, joined EPS Japan, a controlling shareholder of the Company, in March 2022 and was appointed as the Head of Investment Management Office and the Deputy Head of Corporate & Alliance Planning Office in October 2022, where he is responsible for business development and alliances as well as investment management within the group.

Mr. Kusaba joined Mitsubishi Corporation in 2000, and he has been involved in numerous business development, business investment, and alliances in Japan and overseas, mainly focusing in telecom, IT services, and retail industries. When stationed in the United States from 2010 to 2015, he served as the executive vice president of a subsidiary of Mitsubishi Corporation, which offers enterprise IT services, and he was responsible for corporate planning, marketing, and sales. Mr. Kusaba is a colleague of Mr. Miyano, Mr. Hari, Mr. Maezaki, the existing executive Directors and Mr. Shimada, a newly appointed executive Director, in EPS Japan.

Mr. Kusaba completed a Master's Degree of Engineering from Kyoto University. Additionally, he received an MBA degree in Finance from Hitotsubashi University. Mr. Yan, aged 59, is a businessman and has extensive experience in biomedical industry in the People's Republic of China.

Mr. Yan was the chairman of the board of directors and the general manager of from 2013 to 2017 and was as the chairman of the board of directors of during 2018 to 2020, and since 2022 and has been the chairman of the board of directors of since 2021. Mr. Yan graduated from Wuxi Institute of Light Industry. Mr. Saito, aged 61, has been working in Daiichi Sankyo Company, Limited, a Japanese pharmaceutical company the shares of which are listed on the Japanese (Tokyo) Stock Exchange, for almost 34 years.

He moved to the clinical strategic team and became the team leader of anti-hypertensive agents named Olmesartan in Japan from 1997 to 2005 and became a senior vice director to register Olmesartan in the rest of world. From 2012, he has been the vice president of the new drug regulatory affairs department in Japan and the co-chairman of the Global Regulatory Affairs Committee. He has been the vice president of oncology clinical development in Japan from April 2016.

From April 2023, he has been the Corporate Advisor of Daiichi Sankyo. Mr. Saito received his Ph.D. from Chiba University in Japan. He is also the vice chairperson of the ICH Steering Committee of the Japan Pharmaceutical Manufacturers Association.

Following the resignation of Mr. Gao with effect from 1 November 2023, Mr. Miyano, now an executive Director, has been appointed as a LR Authorised Representative. Mr. Xia has resigned as a member of the Audit Committee and Mr. Kusaba has been appointed as a member of the Audit Committee, all with effect from 1 November 2023. The Board would like to extend its warm welcome to Mr. Shimada, Mr. Miyazato, Mr. Chiu, Mr. Kusaba, Mr. Yan and Mr. Saito on their respective appointments.

With effect from 1 November 2023, the role of each of Mr. Hari, now an executive Director, has been changed from the chief financial officer of the Company to the chief accounting officer of the Company; and (ii) Mr. Maezaki, now an executive Director, has been changed from the chief management officer of the Company to the Chief Financial Officer.